1266159-39-0

Upstream product

• 498-94-2 isonipecotic acid 
• 501-53-1 benzyl chloroformate 
• 10314-98-4 1-benzyloxycarbonylpiperidine-4-carboxylic acid 
• 167414-75-7 ethyl <1-(benzyloxycarbonyl)-4-piperidyl>-3-oxopropanoate 
• 3096-81-9 4-phenoxybenzonitrile 
• 10314-99-5 benzyl 4-(chlorocarbonyl)piperidine-1-carboxylate 
• 1266161-61-8 3-amino-3-(4-phenoxyphenyl)acrylonitrile 
• 1413943-83-5 benzyl 4-(5-cyano-4-oxo-6-(4-phenoxyphenyl)-1,4-dihydropyridin-2-yl)piperidine-1-carboxylate 
• 1413943-84-6 benzyl 4-(4-chloro-5-cyano-6-(4-phenoxyphenyl)pyridin-2-yl)piperidine-1-carboxylate 

Downstream Products

• 1266160-29-5 4-(4-phenoxyphenyl)-6-(piperidin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-amine 
• 1413943-82-4 2-(4-(3-amino-4-(4-phenoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)piperidine-1-carbonyl)-3-cyclopropylacrylonitrile 
• 1413943-85-7 3-(4-(3-amino-4-(4-phenoxyphenyl)-1H-pyrazolo[4,3-c]pyridin-6-yl)piperidin-1-yl)-3-oxopropanenitrile 

Relevant academic research and scientific papers

TYROSINE KINASE INHIBITORS

The present disclosure provides compounds and pharmaceutically acceptable salts that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, JAK3, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by

AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF

Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, (I) are useful as kinase modulators, including Btk modulation, wherein A1, A2, A3, R4, are as defined herein.